ReportGem ReportGem

U.S. COMPANY FILING

REGENERON PHARMACEUTICALS, INC. — Form 10-K filed 2026-02-04

Filed: 2026-02-04Company: REGENERON PHARMACEUTICALS, INC.Ticker: REGNExchange: NasdaqForm: 10-KReport period: 2025-12-31SEC accession: 0000872589-26-000008Event: earningsMateriality: 85

Filing text preview

Regeneron reported 2025 revenue of $14.34B, net income of $4.50B, and diluted EPS of $41.48. EYLEA U.S. sales declined 42% due to biosimilar competition, while Dupixent collaboration revenue grew to 41% of total revenue. Risks include biosimilar competition, FDA CRLs, and litigation with Sanofi.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-02-04Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy2026-08-20FDA Approves Regeneron's (REGN) Pasatru for Ultra-Rare FOP in August 2026; Shares Up 5.4%2026-08-2010-Q2026-07-30 · 10-Q8-K2026-07-30 · 8-K10-Q2026-04-29 · 10-Q8-K2026-04-29 · 8-K8-K2026-01-30 · 8-K